Publication
“AI and sustainability - cure or curse?”
While AI can help resolve data issues in sustainable investing, it can create problems such as information breaches and inherent bias in data.
Author:
Publication | March 2017
Treaty/Act: CETA/Bill C-30 (An Act to implement the Comprehensive Economic and Trade Agreement between Canada and the European Union and its Member States and to provide for certain other measures)
Date: March 7, 2017 – Bill C-30 passes second reading in Senate and is referred to Senate’s Standing Committee on Foreign Affairs and International Trade
Major reforms to Canada’s Patent Act are coming as the Canadian Parliament moves one step closer to ratifying the Comprehensive Economic and Trade Agreement (CETA). On March 7, 2017, Bill C-30 (the Act intended to implement CETA into Canadian law) passed its second reading in the Senate, placing it in the final stages of the legislative process. Recent media reports indicate the European Union’s trade chief expects that Canada will ratify CETA within weeks.1
As we reported, CETA and Bill C-30 provide key reforms to the Patent Act affecting the pharmaceutical industry, including:
Are you CETA ready? Contact Norton Rose Fulbright with all your CETA questions.
Bill C-30, Third Reading (House of Commons)
Text of the final Comprehensive Economic and Trade Agreement
1. http://globalnews.ca/news/3324454/canada-eu-to-ratify-free-trade-pact/
Publication
While AI can help resolve data issues in sustainable investing, it can create problems such as information breaches and inherent bias in data.
Publication
The ongoing conflicts and further geopolitical tensions in Eastern Europe and the Middle East, coupled with upcoming elections in a number of key countries including the US and the UK, make 2024 challenging to predict what impact this will have on the insurance sector.
Publication
On 6 September 2022, the European Commission (EC) prohibited Illumina’s acquisition of Grail, bringing to an end the administrative stage of a legal saga that has attracted interest beyond competition law specialists.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023